HR and breast cancer: Sixty-one patients (47.3%) had HR+/HER2- BC, 22 patients (17.1%) had HR+/HER2+ BC, 17 patients (13.2%) had HR-/HER2+ BC, and 29 patients (22.5%) had TNBC.